Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Colby who wrote (21019)	4/21/1999 5:15:00 PM
From: Mkilloran	Respond to of 23519

Colby...Good review...nice to see CS First Boston back in the loop on the conf call Better to see advanced payments...is this the leadin to a partnership with Astra/Zeneca Stronger position for a partner in the USA and Japan Alibra NDA this year ... Pre-mature Ejactulation Phase II studies this year..Larger market than ED marketplace.....this is real good news

To: Colby who wrote (21019)	4/21/1999 6:59:00 PM
From: Edderd	Read Replies (1) \| Respond to of 23519

Colby I think that vivus is for the present slightly expanding their marketing to urologists. We suddenly have a southeast rep covering FL. He doesnt need to see us all the time just keep samples coming and let us know what is happening. Actually this is very efficient since we really don't pay much attention to the reps when they come in with their pitch. I think that they have given up on the PCP since they are not likely to spend the time to dose the patient. Not a bad program. I expect MUSE sale to increase slowly but would like to see Alibra get on the market with a lot of PR. All IMO Ed